Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
Moshe Mittelman(Tel Aviv University), Katharina Modelska(FibroGen (United States)), Anıl Tombak(Mersin Üniversitesi), Krzysztof Mądry(Medical University of Warsaw), Rosemary Harrup(University of Tasmania), John A. Glaspy(University of California, Los Angeles), Tyson Lee(FibroGen (United States)), David H. Henry(Pennsylvania Hospital), Uwe Platzbecker(National Center for Tumor Diseases), Barbara Grabowska(Wroclaw Medical University)
Cited by 5
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655